vicky pratt

passionate about laboratory testing, roses and the beach. my opinions are my own.

[vicky pratt @prattvm1]

Proud of our team

[The Journal of Molecular Diagnostics @JMDiagn]

DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the @AMPath, @TheACMG, @cpicpgx, @Pathologists, @KNMP, ESPT, @pharmgkb, and @PharmVar.

https://t.co/SdqxnMZmX5

[Association for Molecular Pathology @AMPath]

DUE THURSDAY: Your colleagues at #AMPath24 want to hear about your unique, interesting, and/or challenging case studies! Early Bird Case Study submissions are due September 5: https://t.co/f5X01mm6jM.

We hope to hear from you in Vancouver!

#molpath #pathologists

[Sinchita Roy MD PhD @Sinchita_Roy]

Representing @Pathologists as cochair for the upcoming #MolPath guidelines for #lungcancer has been the honor of my academic career 🙏🏽 Make your voice heard during Open Comment Period 🔊 @AMPath @IASLC
https://t.co/ONcqfcUNre

[Association for Molecular Pathology @AMPath]

AMP has filed a lawsuit against the FDA to challenge the final rule on LDTs. AMP stands firm in its commitment to ensuring that regulations enhance patient care without stifling innovation. More Info: https://t.co/3jX85Rj6Sf
#MolPath #LDTs #FDARegulation #PatientCare #CLIAMod

[Association for Molecular Pathology @AMPath]

AMP is honored to announce the recipients of its 2024 Recognition Awards, which will be presented at #AMPath24 in Vancouver this November. Congratulations to Dr. Atul Butte, Dr. Ronald Przygodzki, and Dr. Eric Konnick!

Read the full press release: https://t.co/E8L2e4wmgb

[vicky pratt @prattvm1]

Proud of this group and excited to see our latest recommendations in press.

[Association for Molecular Pathology @AMPath]

AMP PGx WG w/ ACMG, CPIC, CAP, DPWG, ESPT, PharmGKB, & PharmVar have released updated DPYD genotyping recs, emphasizing the importance of variant inclusion in clinical tests. Learn more: https://t.co/6ziHwXPz5X #PGxTesting #MolPath #Pharmacogenomics

[vicky pratt @prattvm1]

Excited to see our workgroup manuscript in press. Proud of our team @AMPath @cpicpgx @PharmVar @pharmgkb @Pathologists @TheACMG

[Association for Molecular Pathology @AMPath]

AMP, ACMG, CPIC, CAP, DPWG, ESPT, PharmGKB, & PharmVar’s latest consensus guideline helps design clinical DPYD genotyping assays, to help identify individuals at risk for severe fluoropyrimidine toxicity. Click to Read: https://t.co/hn1snkvXrx #PGxTesting

[vicky pratt @prattvm1]

@JMDiagn @AMPath Proud to be a part of this team and excited to see the manuscript in press

[The Journal of Molecular Diagnostics @JMDiagn]

New @AMPath Special Article out now in @JMDiagn as an #ArticleinPress!

[vicky pratt @prattvm1]

Join @NASEM_Health on 7/17 for a hybrid workshop on sustaining community engagement in #GenomicsResearch. Register to learn about possible solutions to obstacles to sustained & equitable #CommunityEngagement in genomics: https://t.co/GUEZOo18Y5 #GenomicsRT #CommunityPartnership

[Dr. Marylyn D. Ritchie, PhD @MarylynRitchie]

Excited to host the #CLINPGX2024 meeting with @UPennIBI @pharmgkb and @cpicpgx. We have an exciting meeting planned for the next two days. Thanks to all who traveled to @PennMedicine for the meeting to discuss clinical implementation of pharmacogenomics.

[PharmGKB @pharmgkb]

Great opening to #CLINPGX2024 by @drkellycaudle! Looking forward to a great meeting!

[Association for Molecular Pathology @AMPath]

Include a #GraphicalAbstract with your next submission to @JMDiagn! Promote understanding in a simple panel that is readily sharable on social media for increased views, downloads and citations.

Submission to JMD is free: https://t.co/2ivHyG0Xs4

[Association for Molecular Pathology @AMPath]

AMP is disappointed the FDA decided to release its Final Rule on Laboratory Developed Tests. While we take time to assess the rule's impact on our members and their patients, you can learn about AMP’s long-held position on LDT oversight at: https://t.co/PGb58dp8le

[The Journal of Molecular Diagnostics @JMDiagn]

New #Spotlight: 2024 Updates to American Medical Association’s Current Procedural Terminology Codes for Oncology Panel Testing. From @AMPath member and @JMDiagn Associate Editor @prattvm1.

https://t.co/zIbXJVbPUW

[Esther Babady, PhD @EBabady]

FANTASTIC testimony by Dr. Dara Aisner on the potential impact of the FDA proposed ruling for LDT in today’s Health Subcommittee Hearing on Regulation of Diagnostic Tests ! Thank you @AMPath staff as well… I c u🫶🏽! Replay here 👉🏽 https://t.co/qGlyDbiTjR

[The Journal of Molecular Diagnostics @JMDiagn]

Prenatal testing for variants in genes associated with hereditary cancer risk: laboratory experience and considerations. Authors from @LabCorp.

Full #OpenAccess text: https://t.co/349YhMojeW

[Association for Molecular Pathology @AMPath]

Weekly Resource Spotlight: Interested in Pharmacogenomics? The AMP "Molecular in My Pocket" guide is a must-have. And it's FREE! Grab your copy now: https://t.co/hgcAAU6iY8 #molpath #pathologists #PathX

[Marco L. Leung @marcoleung_]

Check out our latest publication on methylation array in @JMDiagn! We hope it would serve as a useful resource to our peers in the clinical genomic field. @AMPath https://t.co/WfO5RKB7HX

[Association for Molecular Pathology @AMPath]

Need a quick reference guide on Ovarian Cancer Molecular Biomarkers? Check out these new cards produced by the AMP Training and Education Committee: https://t.co/GiLFjT6hrd #molpath #PathX